FR2647343B1 - Nouvelle forme pharmaceutique poreuse et sa preparation - Google Patents

Nouvelle forme pharmaceutique poreuse et sa preparation

Info

Publication number
FR2647343B1
FR2647343B1 FR8906781A FR8906781A FR2647343B1 FR 2647343 B1 FR2647343 B1 FR 2647343B1 FR 8906781 A FR8906781 A FR 8906781A FR 8906781 A FR8906781 A FR 8906781A FR 2647343 B1 FR2647343 B1 FR 2647343B1
Authority
FR
France
Prior art keywords
pct
preparation
pharmaceutical form
novel porous
date nov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8906781A
Other languages
English (en)
French (fr)
Other versions
FR2647343A1 (fr
Inventor
Vanhoeve Magali
Courteille Frederic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rhone Poulenc Sante SA
Original Assignee
Rhone Poulenc Sante SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante SA filed Critical Rhone Poulenc Sante SA
Priority to FR8906781A priority Critical patent/FR2647343B1/fr
Priority to ZA903895A priority patent/ZA903895B/xx
Priority to IE182190A priority patent/IE64370B1/en
Priority to IL9445990A priority patent/IL94459A/en
Priority to IL94460A priority patent/IL94460A0/xx
Priority to AT90401369T priority patent/ATE98867T1/de
Priority to ES90401369T priority patent/ES2062437T3/es
Priority to AU55828/90A priority patent/AU623779B2/en
Priority to KR1019900007369A priority patent/KR0163423B1/ko
Priority to ES90401370T priority patent/ES2054289T3/es
Priority to PCT/FR1990/000359 priority patent/WO1990014089A1/fr
Priority to AU57433/90A priority patent/AU631888B2/en
Priority to AT90401370T priority patent/ATE83663T1/de
Priority to EP90401370A priority patent/EP0399903B1/fr
Priority to DE9090401370T priority patent/DE69000641T2/de
Priority to EP90401369A priority patent/EP0399902B1/fr
Priority to NZ233766A priority patent/NZ233766A/xx
Priority to DK90401370.3T priority patent/DK0399903T3/da
Priority to US07/776,344 priority patent/US5244881A/en
Priority to DE90401369T priority patent/DE69005359T2/de
Priority to DK90401369.5T priority patent/DK0399902T3/da
Priority to DD90340952A priority patent/DD297915A5/de
Priority to IE186290A priority patent/IE63317B1/en
Priority to NO902280A priority patent/NO180517C/no
Priority to CA002017360A priority patent/CA2017360A1/fr
Priority to PT94139A priority patent/PT94139B/pt
Priority to ZA903978A priority patent/ZA903978B/xx
Priority to NZ233784A priority patent/NZ233784A/xx
Priority to JP2131437A priority patent/JP2948271B2/ja
Priority to YU01007/90A priority patent/YU100790A/xx
Priority to PT94138A priority patent/PT94138B/pt
Priority to FI902553A priority patent/FI103712B/fi
Priority to CA002017355A priority patent/CA2017355A1/fr
Priority to PL28532790A priority patent/PL285327A1/xx
Priority to TW079104379A priority patent/TW257672B/zh
Publication of FR2647343A1 publication Critical patent/FR2647343A1/fr
Priority to US07/892,673 priority patent/US5206025A/en
Priority to GR920401770T priority patent/GR3006655T3/el
Application granted granted Critical
Publication of FR2647343B1 publication Critical patent/FR2647343B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
FR8906781A 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation Expired - Fee Related FR2647343B1 (fr)

Priority Applications (37)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation
IE182190A IE64370B1 (en) 1989-05-24 1990-05-21 New porous pharmaceutical form and its preparation
IL9445990A IL94459A (en) 1989-05-24 1990-05-21 Pharmaceutical form and process for its preparation
IL94460A IL94460A0 (en) 1989-05-24 1990-05-21 Pharmaceutical compositions containing imipramine or derivatives thereof
ZA903895A ZA903895B (en) 1989-05-24 1990-05-21 New porous pharmaceutical form and its preparation
DE90401369T DE69005359T2 (de) 1989-05-24 1990-05-22 Poröse Einheitsform und Verfahren.
AU55828/90A AU623779B2 (en) 1989-05-24 1990-05-22 New porus pharmaceutical form and its preparation
KR1019900007369A KR0163423B1 (ko) 1989-05-24 1990-05-22 신규한 다공성 제약학적 형태 및 그의 제조방법
ES90401370T ES2054289T3 (es) 1989-05-24 1990-05-22 Nuevas composiciones a base de imipramina.
PCT/FR1990/000359 WO1990014089A1 (fr) 1989-05-24 1990-05-22 Nouvelles compositions a base d'imipramine
AU57433/90A AU631888B2 (en) 1989-05-24 1990-05-22 New imipramine-based compositions
AT90401370T ATE83663T1 (de) 1989-05-24 1990-05-22 Imipramin enthaltende arzneizubereitungen.
EP90401370A EP0399903B1 (fr) 1989-05-24 1990-05-22 Nouvelles compositions à base d'imipramine
DE9090401370T DE69000641T2 (de) 1989-05-24 1990-05-22 Imipramin enthaltende arzneizubereitungen.
EP90401369A EP0399902B1 (fr) 1989-05-24 1990-05-22 Nouvelle forme pharmaceutique poreuse et sa préparation
NZ233766A NZ233766A (en) 1989-05-24 1990-05-22 Porous, unitary, freeze-dried, solid pharmaceutical forms
DK90401370.3T DK0399903T3 (da) 1989-05-24 1990-05-22 Præparater på basis af imipramin
US07/776,344 US5244881A (en) 1989-05-24 1990-05-22 Compositions based on imipyramine
AT90401369T ATE98867T1 (de) 1989-05-24 1990-05-22 Poroese einheitsform und verfahren.
DK90401369.5T DK0399902T3 (da) 1989-05-24 1990-05-22 Porøs farmaceutisk tilberedningsform og fremstilling deraf
ES90401369T ES2062437T3 (es) 1989-05-24 1990-05-22 Nueva forma farmaceutica porosa y su preparacion.
CA002017355A CA2017355A1 (fr) 1989-05-24 1990-05-23 Compositions a base d'imipramine
NO902280A NO180517C (no) 1989-05-24 1990-05-23 Fremgangsmåte for fremstilling av en fast, farmasöytisk enhetsformulering
DD90340952A DD297915A5 (de) 1989-05-24 1990-05-23 Neue zusammensetzungen auf der grundlage von imipramin
PT94139A PT94139B (pt) 1989-05-24 1990-05-23 Processo de preparacao de composicoes farmaceuticas a base de imipramina
ZA903978A ZA903978B (en) 1989-05-24 1990-05-23 New compositions based on inipramine
NZ233784A NZ233784A (en) 1989-05-24 1990-05-23 Pharmaceutical composition comprising an inclusion compound of imipramine or derivative in cyclodextrin
JP2131437A JP2948271B2 (ja) 1989-05-24 1990-05-23 新規の多孔性製剤及びその製造方法
YU01007/90A YU100790A (en) 1989-05-24 1990-05-23 Inclusion compounds of imipramines or their derivatives or their salts and a process for obtaining imipramine based compounds
PT94138A PT94138B (pt) 1989-05-24 1990-05-23 Processo de preparacao de uma forma farmaceutica porosa a base de ciclodextrina
FI902553A FI103712B (fi) 1989-05-24 1990-05-23 Menetelmä uuden, huokoisen, homogeenisen, lyofilisoidun farmaseuttisen yksikköannosmuodossa olevan valmisteen valmistamiseksi
IE186290A IE63317B1 (en) 1989-05-24 1990-05-23 New compositions based on imipramine
CA002017360A CA2017360A1 (fr) 1989-05-24 1990-05-23 Forme pharmaceutique poreuse et sa preparation
PL28532790A PL285327A1 (en) 1989-05-24 1990-05-24 Method of obtaining a pharmaceutic preparation
TW079104379A TW257672B (enExample) 1989-05-24 1990-05-30
US07/892,673 US5206025A (en) 1989-05-24 1992-06-04 Porous pharmaceutical form and its preparation
GR920401770T GR3006655T3 (enExample) 1989-05-24 1992-12-24

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (2)

Publication Number Publication Date
FR2647343A1 FR2647343A1 (fr) 1990-11-30
FR2647343B1 true FR2647343B1 (fr) 1994-05-06

Family

ID=9381955

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8906781A Expired - Fee Related FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Country Status (24)

Country Link
US (1) US5244881A (enExample)
EP (2) EP0399902B1 (enExample)
JP (1) JP2948271B2 (enExample)
KR (1) KR0163423B1 (enExample)
AT (2) ATE83663T1 (enExample)
AU (2) AU623779B2 (enExample)
CA (2) CA2017360A1 (enExample)
DD (1) DD297915A5 (enExample)
DE (2) DE69000641T2 (enExample)
DK (2) DK0399902T3 (enExample)
ES (2) ES2062437T3 (enExample)
FI (1) FI103712B (enExample)
FR (1) FR2647343B1 (enExample)
GR (1) GR3006655T3 (enExample)
IE (2) IE64370B1 (enExample)
IL (2) IL94459A (enExample)
NO (1) NO180517C (enExample)
NZ (2) NZ233766A (enExample)
PL (1) PL285327A1 (enExample)
PT (2) PT94138B (enExample)
TW (1) TW257672B (enExample)
WO (1) WO1990014089A1 (enExample)
YU (1) YU100790A (enExample)
ZA (2) ZA903895B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69231457T2 (de) * 1991-06-21 2001-05-23 Takeda Chemical Industries Ltd Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
WO1993012769A1 (fr) 1991-12-24 1993-07-08 Yamanouchi Pharmaceutical Co., Ltd. Preparation se desagrageant dans la bouche et elaboration de cette preparation
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
EP0760680A1 (en) * 1994-05-27 1997-03-12 Farmarc Nederland Bv Pharmaceutical composition
CA2281473C (en) * 1997-02-20 2007-01-16 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
DK1052974T3 (da) * 1998-02-05 2009-08-10 Novartis Ag Farmaceutisk sammensætning indeholdende epothilon
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
NZ534039A (en) 2002-01-15 2006-08-31 Ucb Farchim S Formulations of pharmaceutical compositions for oral administration
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
EA200401111A1 (ru) 2002-02-25 2005-02-24 Диффьюжн Фармасьютикалз Ллс Биполярные соли транс-каротиноидов и их применение
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
MX2007010359A (es) 2005-02-24 2008-04-04 Diffusion Pharmaceuticals Llc Trans carotenoides, su sintesis, formulacion y usos.
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
MX2009010988A (es) 2007-04-13 2010-03-15 Diffusion Pharmaceuticals Llc Uso de trans-carotenoides bipolares como un tratamiento previo y en el tratamiento de una enfermedad vascular periferica.
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
CN101878040A (zh) 2007-10-31 2010-11-03 扩散药品有限公司 一类促进小分子扩散的新型治疗剂
RU2011112926A (ru) * 2008-09-05 2012-10-10 МакНЕЙЛ-ППС, ИНК. (US) Способ изготовления таблеток цетиризина
EP3539542B1 (en) 2009-06-22 2023-04-19 Diffusion Pharmaceuticals LLC Diffusion enhancing compounds and their use with a thrombolytic
WO2011152869A1 (en) 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
SG10201507554RA (en) * 2010-09-13 2015-10-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (enExample) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
EP0204003A4 (en) * 1984-11-27 1987-06-03 Dainippon Pharmaceutical Co 2-(1-piperazinyl)-4-substituted phenylquinoline derivatives, process for their preparation, and medicinal composition containing same.
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
FI103712B1 (fi) 1999-08-31
DE69005359D1 (de) 1994-02-03
IE901821L (en) 1990-11-24
TW257672B (enExample) 1995-09-21
IL94459A0 (en) 1991-03-10
AU5582890A (en) 1991-01-10
ATE98867T1 (de) 1994-01-15
CA2017355A1 (fr) 1990-11-24
ES2062437T3 (es) 1994-12-16
YU100790A (en) 1992-05-28
FI902553A0 (fi) 1990-05-23
ES2054289T3 (es) 1994-08-01
AU623779B2 (en) 1992-05-21
DK0399903T3 (da) 1993-02-08
ZA903978B (en) 1991-03-27
US5244881A (en) 1993-09-14
KR900017570A (ko) 1990-12-19
FR2647343A1 (fr) 1990-11-30
ATE83663T1 (de) 1993-01-15
JP2948271B2 (ja) 1999-09-13
IE901862L (en) 1990-11-24
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
NO902280L (no) 1990-11-26
IL94459A (en) 1995-01-24
PT94138A (pt) 1991-01-08
WO1990014089A1 (fr) 1990-11-29
AU5743390A (en) 1990-12-18
IE64370B1 (en) 1995-07-26
PT94139A (pt) 1991-01-08
DE69000641D1 (de) 1993-02-04
IE63317B1 (en) 1995-04-05
PT94138B (pt) 1996-12-31
DK0399902T3 (da) 1994-02-14
AU631888B2 (en) 1992-12-10
CA2017360A1 (fr) 1990-11-24
IL94460A0 (en) 1991-03-10
GR3006655T3 (enExample) 1993-06-30
KR0163423B1 (ko) 1998-12-01
EP0399902B1 (fr) 1993-12-22
NO180517C (no) 1997-05-07
DE69000641T2 (de) 1993-06-09
NO902280D0 (no) 1990-05-23
NZ233784A (en) 1993-04-28
EP0399903A1 (fr) 1990-11-28
ZA903895B (en) 1991-03-27
NO180517B (no) 1997-01-27
PT94139B (pt) 1996-12-31
JPH0356412A (ja) 1991-03-12
NZ233766A (en) 1991-08-27
PL285327A1 (en) 1991-02-11
DE69005359T2 (de) 1994-05-05
DD297915A5 (de) 1992-01-30
EP0399903B1 (fr) 1992-12-23

Similar Documents

Publication Publication Date Title
FR2647343B1 (fr) Nouvelle forme pharmaceutique poreuse et sa preparation
NZ229832A (en) Condensed heterocyclic compounds, preparation and pharmaceutical compositions thereof
IL68230A0 (en) Quaternary 6,11-dihydro-dibenzo(b,e)thiepine-11-n-alkyl-norscopine ethers,their preparation and pharmaceutical compositions containing them
ES2157993T3 (es) Benzoilguanidinas, su preparacion y su uso en medicamentos.
IL98262A (en) Chromone derivatives and pharmaceutical compositions containing them
DK0387821T3 (da) 2-Alkyl-4-arylmethylchinoliner, deres anvendelse og lægemidler fremstillet hermed
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
ES2039211T3 (es) Nuevos n-glicosilamidoderivados, procedimientos para su obtencion y su empleo como medicamentos.
MX9202432A (es) Compuestos de 4,5-dihidro-1,4-benzotiazepin-3(2h)onas, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
IT1178800B (it) Composizioni farmaceutiche e loro uso come midriatici
FR2701709B1 (fr) Forme purifiée de streptograminés, sa préparation et les compositions pharmaceutiques qui la contiennent.
MX9102627A (es) Composicion farmaceutica de dobutamina para administracion transdermica.
MX9203581A (es) Composiciones farmaceuticas de indolinas 3,3-disubstituidas, para administracion nasal.
DZ1797A1 (fr) Forme purifiér de streptogramines, sa préparation et les compositions pharmaceutiques qui la contiennent.
IT8920758A0 (it) 1,5 benzotiazepin derivati, processi per la loro preparazione e composizioni farmaceutiche.
MX9200443A (es) Hidrato de 6-ciclohexil-2'-o-metil-adenosina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8920835A0 (it) Agente antitussivo e mucoregolatore, sua preparazione e composizioni farmaceutiche.

Legal Events

Date Code Title Description
ST Notification of lapse
ST Notification of lapse